Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Concordia Healthcare Corp. T.CXR

Primary Symbol: T.CXR.R

Concordia Healthcare Corp. > Rebrand As ADVANZ PHARMA Following Its Recapitalization

{{labelSign}}  Favorites

October 16, 2018 - 03:45 PM
368 Reads
Post# 28812942

Rebrand As ADVANZ PHARMA Following Its Recapitalization


CXR Intention To Rebrand As ADVANZ PHARMA Following Its Successful Recapitalization

Canada NewsWire

-  ADVANZ PHARMA represents the Company's vision to go beyond 
expectations to bring sustainable value to customers, healthcare providers, 
and patients -

MISSISSAUGA, ONOct. 9, 2018  /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), announced today its intention to change its name as part of a global rebrand in support of its strategy and vision. Subject to the customary approvals, including stock exchange and shareholder approvals, the Company intends to rebrand as ADVANZ PHARMA during the fourth quarter of 2018. 

ADVANZ PHARMA (Concordia International Corp.), will re-focus on delivering sustainable value across its portfolio of specialty generic and legacy branded, off patent medicines.

ADVANZ PHARMA will aim to build on the Company's current capabilities and global footprint across more than 90 countries, to enable it to meet the increasingly complex needs of global healthcare systems.

Graeme Duncan, Chief Executive Officer said: "ADVANZ PHARMA is more than just a new corporate brand. We believe it truly represents the Company's new vision and values. Leveraging a new corporate identity, leadership team and capital structure, we are aiming to go beyond the fulfillment of orders of our medicines to become a trusted and respected partner to our customers, healthcare providers, and patients."

In addition to ensuring continued supply of its diverse range of high quality, established medicines, the Company will focus on expanding its global presence in order to provide a platform for future growth.

"Through the expansion of our extensive portfolio and our acquisition strategy, we will look to provide greater access to medicines for patients, and sustainable value for healthcare providers," Mr Duncan continued. "We believe that our strong financial position, and supportive shareholder base, combined with our impressive heritage and experience, will see us deliver a progressive company that is ready for the future. We will be looking to utilise our strong balance sheet to further build out our pipeline of medicines and acquire both companies and standalone medicines that allow us to continue to meet the present and future needs of the healthcare environment."

Mr Duncan, who is unveiling the proposed corporate identity to global partners, suppliers and customers at CPhI Europe in Madrid, Spain, concluded, "We aim to be the most idea-generative company in the generics industry and look forward to working towards this goal with all industry partners, and we think ADVANZ PHARMA represents this. In transitioning to a new corporate brand and global strategy, we expect that our commitment to our refreshed vision will offer true value to our core stakeholders and healthcare systems."

About Concordia

Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. Going forward, the Company is focused on becoming a leader in European specialty, off-patent medicines.

Concordia operates out of facilities in Mississauga, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, BarbadosLondon, England and Mumbai, India.